FANAPT
Total Payments
$28.3M
Transactions
29,251
Doctors
10,789
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $6.2M | 21,209 | 8,409 |
| 2023 | $1.7M | 1,973 | 1,155 |
| 2022 | $12.7M | 2,396 | 1,418 |
| 2021 | $7.3M | 2,412 | 1,373 |
| 2020 | $337,880 | 1,261 | 592 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $24.3M | 456 | 86.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.4M | 803 | 8.7% |
| Food and Beverage | $908,903 | 25,257 | 3.2% |
| Travel and Lodging | $584,666 | 1,636 | 2.1% |
| Education | $9,092 | 1,099 | 0.0% |
Payments by Type
Research
$24.3M
456 transactions
General
$3.9M
28,795 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| EVALUATION OF EFFICACY AND SAFETY OF ILOPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER | Vanda Pharmaceuticals Inc. | $22.2M | 2 |
| SAFETY AND TOLERABILITY OF OPEN-LABELED ILOPERIDONE IN ADOLESCENTS | Vanda Pharmaceuticals Inc. | $772,162 | 0 |
| A STUDY TO EVALUATEILOPERIDONELONG-ACTING INJECTION (LAI) FOR THE TREATMENT OF SCHIZOPHRENIA | Vanda Pharmaceuticals Inc. | $484,168 | 1 |
| AN OPEN-LABEL, SEQUENTIAL DOSE ESCALATION COHORT STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ILOPERIDONE LONG ACTING INJECTABLE IN SUBJECTS WITH SCHIZOPHRENIA | Vanda Pharmaceuticals Inc. | $325,381 | 1 |
| AN OPEN-LABEL, SEQUENTIAL DOSE ESCALATION COHORT STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ILOPERIDONE LONG ACTING INJECTABLE (LAI) IN SUBJECTS WITH SCHIZOPHRENIA | Vanda Pharmaceuticals Inc. | $323,921 | 0 |
| A STUDY TO EVALUATE ILOPERIDONE LONG-ACTING INJECTION (LAI) FOR THE TREATMENT OF SCHIZOPHRENIA | Vanda Pharmaceuticals Inc. | $122,983 | 1 |
| A SAFETY/TOLERANCE STUDY TO EVALUATE A NEW TITRATION SCHEME IN PATIENTS WITH BIPOLAR DISORDER OR SCHIZOPHRENIA. | Vanda Pharmaceuticals Inc. | $54,984 | 0 |
| A STUDY TO EVALUATE ILOPERIDONE FOR THE TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS | Vanda Pharmaceuticals Inc. | $39,056 | 0 |
| STUDY OF CYTOCHROME P450 2D6 (CYP2D6) PATIENTS WITH SCHIZOPHRENIA | Vanda Pharmaceuticals Inc. | $22,047 | 0 |
| AN OPEN-LABEL, SEQUENTIAL COHORTS, FLEXIBLE DOSE STUDY TO EVALUATE THE TOLERABILITY, SAFETY AND PHARMACOKINETICS OF ILOPERIDONE IN ELDERLY PATIENTS WITH PARKINSON'S DISEASE PSYCHOSIS (PDP) | Vanda Pharmaceuticals Inc. | $600.00 | 1 |
Top Doctors Receiving Payments for FANAPT — Page 5
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Psychiatry | Plano, TX | $745.81 | 3 |
| , MD | Psychiatry | Warwick, RI | $657.95 | 18 |
| , MD | Psychiatry | Cuyahoga Falls, OH | $651.58 | 31 |
| , RNCS | Psychiatric/Mental Health, Adult | Wakefield, MA | $639.10 | 29 |
| , M.D | Psychiatry | Amherst, NY | $624.44 | 25 |
| , M.D | Psychiatry | Cranston, RI | $620.69 | 13 |
| , M.D | Psychiatry | Orange, CA | $619.34 | 5 |
| , MD | Psychiatry | Lake Oswego, OR | $610.23 | 24 |
| , D.N.P | Psychiatric/Mental Health | Englewood, NJ | $602.45 | 10 |
| , MD | Psychiatry | Philadelphia, PA | $600.00 | 1 |
| , DNP, PMHNP-BC, NP | Psychiatric/Mental Health | Charlotte, NC | $599.40 | 14 |
| , APRN | Psychiatric/Mental Health | Fort Mill, SC | $595.18 | 13 |
| , M.D | Internal Medicine | O Fallon, MO | $586.78 | 5 |
| , CRNP | Psychiatric/Mental Health | Hoover, AL | $579.45 | 17 |
| , MD | Psychiatry | New York, NY | $571.29 | 24 |
| , MD | Psychiatry | Amherst, NY | $566.77 | 32 |
| , NURSE PRACTITIONER | Primary Care | Putnam, CT | $565.26 | 24 |
| , MD | Psychiatry | Beverly Hills, CA | $556.16 | 16 |
| , PMHNP-BC | Addiction (Substance Use Disorder) | Pasadena, CA | $555.56 | 10 |
| Rosanna Carter | Psychiatric/Mental Health | Buffalo, NY | $554.17 | 17 |
| , PMHNP | Psychiatric/Mental Health | Kissimmee, FL | $548.13 | 6 |
| , MD | Internal Medicine | Bronx, NY | $545.78 | 26 |
| Hui Hu | Psychiatric/Mental Health | Norwich, CT | $544.45 | 16 |
| , M.D | Specialist | San Antonio, TX | $537.40 | 14 |
| , APN | Psychiatric/Mental Health | Grinnell, IA | $529.77 | 9 |
Ad
Manufacturing Companies
- Vanda Pharmaceuticals Inc. $28.3M
Product Information
- Type Drug
- Total Payments $28.3M
- Total Doctors 10,789
- Transactions 29,251
About FANAPT
FANAPT is a drug associated with $28.3M in payments to 10,789 healthcare providers, recorded across 29,251 transactions in the CMS Open Payments database. The primary manufacturer is Vanda Pharmaceuticals Inc..
Payment data is available from 2020 to 2024. In 2024, $6.2M was paid across 21,209 transactions to 8,409 doctors.
The most common payment nature for FANAPT is "Unspecified" ($24.3M, 86.0% of total).
FANAPT is associated with 10 research studies, including "EVALUATION OF EFFICACY AND SAFETY OF ILOPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER" ($22.2M).